Biogen Idec, Inc. (BIIB) Tops Q3 Adj-EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $250.69 -1.24%
Revenue Growth %: +4.3%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 219.4M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +4.3%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 219.4M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q3 EPS of $1.61, ex-items, $0.08 better than the analyst estimate of $1.53. Revenue for the quarter came in at $1.31 billion versus the consensus estimate of $1.27 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $244 at BofA Securities
- Booz Allen Hamilton (BAH) Tops Q2 EPS by 28c, Misses on Revenue
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
Create E-mail Alert Related Categories
Earnings, Hot EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
